(INSM) Insmed - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 23.656m USD | Total Return: 58.2% in 12m

Antibiotics, Enzyme Inhibitors, Gene Therapies, Monoclonal Antibodies
Total Rating 27
Safety 25
Buy Signal -0.47
Biotechnology
Industry Rotation: -18.1
Market Cap: 23.7B
Avg Turnover: 317M
Risk 3d forecast
Volatility47.5%
VaR 5th Pctl7.45%
VaR vs Median-6.08%
Reward TTM
Sharpe Ratio1.00
Rel. Str. IBD15.3
Rel. Str. Peer Group13.8
Character TTM
Beta0.042
Beta Downside-0.198
Hurst Exponent0.363
Drawdowns 3y
Max DD52.06%
CAGR/Max DD1.51
CAGR/Mean DD7.91
EPS (Earnings per Share) EPS (Earnings per Share) of INSM over the last years for every Quarter: "2021-03": -0.89, "2021-06": -0.91, "2021-09": -0.89, "2021-12": -0.95, "2022-03": -0.8, "2022-06": -0.8, "2022-09": -1.09, "2022-12": -1.21, "2023-03": -1.17, "2023-06": -1.78, "2023-09": -1.11, "2023-12": -1.28, "2024-03": -1.06, "2024-06": -1.94, "2024-09": -1.27, "2024-12": -1.32, "2025-03": -1.42, "2025-06": -1.7, "2025-09": -1.75, "2025-12": -1.54, "2026-03": -0.76,
EPS CAGR: 0.83%
EPS Trend: -30.2%
Last SUE: 0.64
Qual. Beats: 0
Revenue Revenue of INSM over the last years for every Quarter: 2021-03: 40.214, 2021-06: 45.366, 2021-09: 46.757, 2021-12: 56.124, 2022-03: 53.107, 2022-06: 65.221, 2022-09: 67.73, 2022-12: 59.3, 2023-03: 65.214, 2023-06: 77.229, 2023-09: 79.072, 2023-12: 83.693, 2024-03: 75.5, 2024-06: 90.34, 2024-09: 93.425, 2024-12: 104.442, 2025-03: 92.823, 2025-06: 107.415, 2025-09: 142.342, 2025-12: 263.843, 2026-03: 305.964,
Rev. CAGR: 51.01%
Rev. Trend: 88.0%
Last SUE: 0.56
Qual. Beats: 0

Warnings

Share dilution 19.1% YoY

Interest Coverage Ratio -14.3 is critical

Altman Z'' -13.61 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: INSM Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for rare and serious diseases, primarily within the respiratory and orphan disease sectors. The company currently markets ARIKAYCE for refractory nontuberculous mycobacterial (NTM) lung infections and maintains a late-stage pipeline including brensocatib for bronchiectasis and treprostinil palmitil for pulmonary hypertension. Its research expansion includes gene therapy platforms targeting Duchenne muscular dystrophy and amyotrophic lateral sclerosis.

The biotechnology sector typically requires high research and development (R&D) expenditure, as companies must navigate multi-phase clinical trials and stringent regulatory approvals before achieving commercial scale. Insmed utilizes a specialized commercialization model that targets niche patient populations with high unmet medical needs, often benefiting from orphan drug designations which provide market exclusivity periods.

For a more comprehensive look at these pipeline developments, ValueRay offers additional data points.

Headlines to Watch Out For
  • ARIKAYCE commercial expansion drives core revenue growth in global refractory lung markets
  • Brensocatib Phase 3 clinical outcomes determine long-term valuation in bronchiectasis treatment
  • Treprostinil palmitil regulatory approvals impact entry into pulmonary hypertension markets
  • High research and development expenditures necessitate future capital raises or partnerships
  • Gene therapy pipeline advancement influences speculative premium and long-term asset diversification
Piotroski VR‑10 (Strict) 2.0
Net Income: -1.18b TTM > 0 and > 6% of Revenue
FCF/TA: -0.46 > 0.02 and ΔFCF/TA -2.06 > 1.0
NWC/Revenue: 152.8% < 20% (prev 305.3%; Δ -152.6% < -1%)
CFO/TA -0.43 > 3% & CFO -895.7m > Net Income -1.18b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.47 > 1.5 & < 3
Outstanding Shares: last quarter (215.5m) vs 12m ago 19.14% < -2%
Gross Margin: 81.56% > 18% (prev 0.76%; Δ 8.08k% > 0.5%)
Asset Turnover: 42.26% > 50% (prev 21.14%; Δ 21.12% > 0%)
Interest Coverage Ratio: -14.31 > 6 (EBITDA TTM -1.14b / Interest Expense TTM 80.9m)
Altman Z'' -13.61
A: 0.60 (Total Current Assets 1.61b - Total Current Liabilities 361.0m) / Total Assets 2.08b
B: -2.79 (Retained Earnings -5.80b / Total Assets 2.08b)
C: -0.60 (EBIT TTM -1.16b / Avg Total Assets 1.94b)
D: -4.23 (Book Value of Equity -5.80b / Total Liabilities 1.37b)
Altman-Z'' Score: -13.61 = D
Beneish M -1.78
DSRI: 1.74 (Receivables 178.6m/47.7m, Revenue 819.6m/381.0m)
GMI: 0.94 (GM 81.56% / 76.49%)
AQI: 1.01 (AQ_t 0.16 / AQ_t-1 0.16)
SGI: 2.15 (Revenue 819.6m / 381.0m)
TATA: -0.14 (NI -1.18b - CFO -895.7m) / TA 2.08b)
Beneish M-Score: -1.78 (Cap -4..+1) = B
What is the price of INSM shares? As of May 20, 2026, the stock is trading at USD 107.41 with a total of 3,645,879 shares traded.
Over the past week, the price has changed by -7.41%, over one month by -24.79%, over three months by -33.29% and over the past year by +58.24%.
Is INSM a buy, sell or hold? Insmed has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy INSM.
  • StrongBuy: 14
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the INSM price?
Analysts Target Price 201 87.1%
Insmed (INSM) - Fundamental Data Overview as of 19 May 2026
P/E Forward = 16.3666
P/S = 28.8646
P/B = 31.1666
P/EG = 1.0916
Revenue TTM = 819.6m USD
EBIT TTM = -1.16b USD
EBITDA TTM = -1.14b USD
Long Term Debt = 541.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 14.4m USD (from shortTermDebt, last quarter)
Debt = 748.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -475.1m USD (recalculated: Debt 748.4m - CCE 1.22b)
Enterprise Value = 23.18b USD (23.66b + Debt 748.4m - CCE 1.22b)
Interest Coverage Ratio = -14.31 (Ebit TTM -1.16b / Interest Expense TTM 80.9m)
EV/FCF = -24.36x (Enterprise Value 23.18b / FCF TTM -951.6m)
FCF Yield = -4.11% (FCF TTM -951.6m / Enterprise Value 23.18b)
 FCF Margin = -116.1% (FCF TTM -951.6m / Revenue TTM 819.6m)
 Net Margin = -144.4% (Net Income TTM -1.18b / Revenue TTM 819.6m)
Gross Margin = 81.56% ((Revenue TTM 819.6m - Cost of Revenue TTM 151.2m) / Revenue TTM)
Gross Margin QoQ = 83.82% (prev 83.24%)
Tobins Q-Ratio = 11.17 (Enterprise Value 23.18b / Total Assets 2.08b)
Interest Expense / Debt = 2.68% (Interest Expense 20.1m / Debt 748.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -915.2m (EBIT -1.16b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.47 (Total Current Assets 1.61b / Total Current Liabilities 361.0m)
Debt / Equity = 1.06 (Debt 748.4m / totalStockholderEquity, last quarter 704.9m)
 Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -475.1m / EBITDA -1.14b)
 Debt / FCF = 0.50 (negative FCF - burning cash) (Net Debt -475.1m / FCF TTM -951.6m)
 Total Stockholder Equity = 909.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -61.04% (Net Income -1.18b / Total Assets 2.08b)
RoE = -130.1% (Net Income TTM -1.18b / Total Stockholder Equity 909.8m)
RoCE = -79.86% (EBIT -1.16b / Capital Employed (Equity 909.8m + L.T.Debt 541.0m))
 RoIC = -60.30% (negative operating profit) (NOPAT -915.2m / Invested Capital 1.52b)
 WACC = 6.01% (E(23.66b)/V(24.40b) * Re(6.13%) + D(748.4m)/V(24.40b) * Rd(2.68%) * (1-Tc(0.21)))
Discount Rate = 6.13% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 100.00 | Cagr: 19.32%
 [DCF] Fair Price = unknown (Cash Flow -951.6m)
 EPS Correlation: -30.19 | EPS CAGR: 0.83% | SUE: 0.64 | # QB: 0
Revenue Correlation: 88.01 | Revenue CAGR: 51.01% | SUE: 0.56 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.78 | Chg30d=+1.01% | Revisions=+0% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.60 | Chg30d=-3.80% | Revisions=+0% | Analysts=12
EPS current Year (2026-12-31): EPS=-2.76 | Chg30d=+1.18% | Revisions=-11% | GrowthEPS=+57.0% | GrowthRev=+180.5%
EPS next Year (2027-12-31): EPS=0.37 | Chg30d=-49.54% | Revisions=-33% | GrowthEPS=+113.3% | GrowthRev=+64.3%
[Analyst] Revisions Ratio: -33%